Seagen | 141.9300 / -0.64% |
Date/Time | 04/12 / 17:50 |
Chg. / Chg.(%) | -0.9200 / -0.64% |
Bid | 141.8400 / 100 |
Ask | 142.0400 / 200 |
Open | 142.3100 |
Previous Close | 142.8500 |
High | 142.3500 |
Low | 139.4600 |
Volume [USD] | 32,208,122.8353 |
Volume [Units] | 298,782 |
Price fixings | 1203 |
ISIN | US81181C1045 |
Security | SGEN |
Exchange | NASDAQ |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 141.9300 | ![]() |
298,782 |
IEX | 142.13 | ![]() |
19,122 |
Cboe US | 141.97 | ![]() |
6,721 |
TradeGate | 120.02 | ![]() |
35 |
München | 117.44 | ![]() |
0 |
Berlin | 117.44 | ![]() |
0 |
Frankfurt | 117.7600 | ![]() |
0 |
Stuttgart | 119.680 | ![]() |
|
Lang & Schwa.. | 118.74 | ![]() |
|
gettex | 118.440 | ![]() |
|
Mexico | 3,192.00 | ![]() |
21 |
News
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
04/09/2021 / 22:00 - GlobeNewswire - Fight Colorectal Cancer Urges Americans, “No Excuses! Get Screened!” after 10,000 excess cancer deaths are expected over the next decade
03/02/2021 / 20:58 - GlobeNewswire - Genmab Publishes 2020 Annual Report
02/23/2021 / 17:00 - GlobeNewswire - US opens lower ahead of economic updates
02/12/2021 / 15:30 - TeleTrader - Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
02/10/2021 / 22:05 - GlobeNewswire